Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Cancer02:18

Cancer

53.4K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.4K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

9.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.9K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exercise Capacity, Endothelial Function, Muscle Mass, and Strength in Pediatric Patients With Fontan Circulation.

CJC pediatric and congenital heart disease·2026
Same author

Redefining therapeutic horizons in thymic epithelial tumors: precision, combinations, and emerging biology.

NPJ precision oncology·2026
Same author

Beyond Water, Rest, and Shade: Advancing Farmworker Heat Protection Through Partnership.

American journal of industrial medicine·2026
Same author

Heterogeneity of Treatment Effects Across Nine Glucose-Lowering Drug Classes in Type 2 Diabetes: Extension of the LEGEND-T2DM Network Study.

Diabetes, obesity & metabolism·2026
Same author

Semaglutide and Neovascular Age-Related Macular Degeneration Among Adults with Type 2 Diabetes: An OHDSI Network Study.

Ophthalmology·2026
Same author

Predictors for Positive Repeated Urine Culture in Patients with Negative Initial Urine Culture before Endoscopic Lithotripsy.

Surgical infections·2026

Related Experiment Video

Updated: Jan 6, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.1K

Molecularly Targeted Cancer Medications and Kidney Health.

Susan Ziolkowski1, Jin Long2, Yutong Zhong2

  • 1Department of Medicine, Nephrology, Stanford University, Stanford, California.

JAMA Network Open
|November 6, 2025
PubMed
Summary

Molecularly targeted cancer drugs may increase kidney dysfunction risk. This study found higher rates in patients taking these medications compared to those without cancer.

More Related Videos

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.3K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.7K

Related Experiment Videos

Last Updated: Jan 6, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.1K
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.3K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.7K

Area of Science:

  • Oncology
  • Nephrology
  • Pharmacology

Background:

  • Oral molecularly targeted cancer medications are increasingly used.
  • Product labels often note increased serum creatinine (sCr), potentially due to altered tubular secretion rather than acute kidney injury.

Purpose of the Study:

  • To determine the 2-year incidence and relative rates of progressive kidney dysfunction in patients treated with specific molecularly targeted cancer medications.
  • To investigate if the observed increase in sCr reflects true kidney injury or a reversible change in handling.

Main Methods:

  • Retrospective cohort study comparing adult patients treated with CDK4/6 inhibitors, PARP inhibitors, or specific TKIs with propensity score-matched cancer-free patients.
  • Estimated glomerular filtration rate (eGFR) was calculated and analyzed from days 1-60 post-drug start to define baseline, accounting for potential sCr handling changes.
  • Progressive kidney dysfunction was defined as a sustained 30% decline in eGFR or development of end-stage kidney disease.

Main Results:

  • The incidence of progressive kidney dysfunction was higher in the treated cohort (44 per 1000 person-years) compared to controls (38 per 1000 person-years; HR, 1.4).
  • Higher rates were observed with CDK4/6 inhibitors, specific EGFR inhibitors, VEGFR inhibitors, and BRAF inhibitors.
  • This increased risk persisted even in patients without a significant sCr rise at drug start and without concurrent chemotherapy or immunotherapy.

Conclusions:

  • Patients treated with certain molecularly targeted anticancer medications face a higher risk of progressive kidney dysfunction.
  • The findings highlight the importance of monitoring kidney function in these patients, considering potential drug-induced nephrotoxicity beyond reversible sCr changes.